Hemminki A - Search Results

1

Effective Combination Immunotherapy with Oncolytic Adenovirus and Anti-PD-1 for Treatment of Human and Murine Ovarian Cancers.

Heiniö C, Clubb J, Kudling T, Quixabeira D, Cervera-Carrascon V, Havunen R, Grönberg-Vähä-Koskela S, Santos JM, Tapper J, Kanerva A, Hemminki A. Heiniö C, et al. Among authors: hemminki a. Diseases. 2022 Aug 8;10(3):52. doi: 10.3390/diseases10030052. Diseases. 2022. PMID: 35997357 Free PMC article.

2

Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells.

Kanerva A, Mikheeva GV, Krasnykh V, Coolidge CJ, Lam JT, Mahasreshti PJ, Barker SD, Straughn M, Barnes MN, Alvarez RD, Hemminki A, Curiel DT. Kanerva A, et al. Among authors: hemminki a. Clin Cancer Res. 2002 Jan;8(1):275-80. Clin Cancer Res. 2002. PMID: 11801569

3

Treatment of ovarian cancer with a tropism modified oncolytic adenovirus.

Bauerschmitz GJ, Lam JT, Kanerva A, Suzuki K, Nettelbeck DM, Dmitriev I, Krasnykh V, Mikheeva GV, Barnes MN, Alvarez RD, Dall P, Alemany R, Curiel DT, Hemminki A. Bauerschmitz GJ, et al. Among authors: hemminki a. Cancer Res. 2002 Mar 1;62(5):1266-70. Cancer Res. 2002. PMID: 11888888

4

The flt-1 promoter for transcriptional targeting of teratocarcinoma.

Bauerschmitz GJ, Nettelbeck DM, Kanerva A, Baker AH, Hemminki A, Reynolds PN, Curiel DT. Bauerschmitz GJ, et al. Among authors: hemminki a. Cancer Res. 2002 Mar 1;62(5):1271-4. Cancer Res. 2002. PMID: 11888889

5

Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses.

Kanerva A, Wang M, Bauerschmitz GJ, Lam JT, Desmond RA, Bhoola SM, Barnes MN, Alvarez RD, Siegal GP, Curiel DT, Hemminki A. Kanerva A, et al. Among authors: hemminki a. Mol Ther. 2002 Jun;5(6):695-704. doi: 10.1006/mthe.2002.0599. Mol Ther. 2002. PMID: 12027553 Free article.

6

Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors.

Haviv YS, Blackwell JL, Kanerva A, Nagi P, Krasnykh V, Dmitriev I, Wang M, Naito S, Lei X, Hemminki A, Carey D, Curiel DT. Haviv YS, et al. Among authors: hemminki a. Cancer Res. 2002 Aug 1;62(15):4273-81. Cancer Res. 2002. PMID: 12154029

7

CD40 is expressed on ovarian cancer cells and can be utilized for targeting adenoviruses.

Hakkarainen T, Hemminki A, Pereboev AV, Barker SD, Asiedu CK, Strong TV, Kanerva A, Wahlfors J, Curiel DT. Hakkarainen T, et al. Among authors: hemminki a. Clin Cancer Res. 2003 Feb;9(2):619-24. Clin Cancer Res. 2003. PMID: 12576427

8

Modulation of coxsackie-adenovirus receptor expression for increased adenoviral transgene expression.

Hemminki A, Kanerva A, Liu B, Wang M, Alvarez RD, Siegal GP, Curiel DT. Hemminki A, et al. Cancer Res. 2003 Feb 15;63(4):847-53. Cancer Res. 2003. PMID: 12591736

9

A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model.

Hemminki A, Kanerva A, Kremer EJ, Bauerschmitz GJ, Smith BF, Liu B, Wang M, Desmond RA, Keriel A, Barnett B, Baker HJ, Siegal GP, Curiel DT. Hemminki A, et al. Mol Ther. 2003 Feb;7(2):163-73. doi: 10.1016/s1525-0016(02)00049-7. Mol Ther. 2003. PMID: 12597904 Free article.

10

The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapy.

Barker SD, Coolidge CJ, Kanerva A, Hakkarainen T, Yamamoto M, Liu B, Rivera AA, Bhoola SM, Barnes MN, Alvarez RD, Curiel DT, Hemminki A. Barker SD, et al. Among authors: hemminki a. J Gene Med. 2003 Apr;5(4):300-10. doi: 10.1002/jgm.341. J Gene Med. 2003. PMID: 12692864

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

348 results

Search Page

Filters